drugset / Trial / NCT04264442

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442

Phase 2 Terminated 76 enrolled Fulcrum Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label extension to evaluate the safety and tolerability of long-term dosing of Losmapimod in patients with FSHD1 who participated in the ReDux4 study.

Timeline

Start
2020-02-13
Primary completion
2024-11-07
Completion
2024-11-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Losmapimod Small molecule 15 mg Oral